Preclinical Obesity Research: Best Practice in Model Selection and Study Design
Presenter: Fred Beasley, PhD
Preclinical obesity research and drug development is complex and challenging. From appropriate model selection to long term dosing requirements, further complications such as natural subject-to-subject variability, and regressions to and from an obese state arise.
This webinar presents a range of solutions to these challenges. Dr Fred Beasley explores how to select the most appropriate rodent models for your obesity studies, including recapitulating human obesity and underlying genetics, best fit for study criteria, and specific diet acceptance.
Watch this Webinar to Learn:
- How to choose the right rodent models and study design for preclinical anti-obesity agent drug development
- The pros and cons of polygenic obesity models with intact leptin pathways versus more conventional monogenic models of obesity
- Strategies to identify models that fit study criteria and also accept the specific diets required for your study
- Model recommendations based on different drug modes of action
Who Should Watch:
- Preclinical obesity researchers looking to optimize model selection and obesity study design
- Preclinical scientists who want to learn the pros and cons of polygenic vs conventional obesity models
- Drug developers who want to learn how to select obesity models based on mode of action of their novel agents
About The Presenter:
Dr Fred Beasley is the Director of Scientific Engagement for the Cardiovascular and Metabolic Disease Division at Crown Bioscience, where he uses his training in animal model development and direction to assist in study design and client/operations communications.
Prior to joining CrownBio, Fred served as in vivo biologist at the NASH/inflammation startup Jecure Therapeutics (acquired by Genentech in 2018); and as a Study Director at BTS Research, southern California’s sole CRO provider of preclinical NHP models.
Fred obtained his PhD in Microbiology and Immunology at the University of Western Ontario, and completed postdoctoral training at UC San Diego and at Calibr/Scripps Research Institute. His research efforts focused on developing rodent models to evaluate small molecule drugs against bacterial and parasitic pathogens, and he is an author on over 20 publications.